## **Core Concept**
The patient's presentation suggests a diagnosis of **Basal Cell Carcinoma (BCC)**, a type of skin cancer strongly associated with **chronic sun exposure**. BCC is characterized by a slowly growing, locally destructive lesion that rarely metastasizes but can cause significant local damage if left untreated.
## **Why the Correct Answer is Right**
The correct answer involves drugs approved for the treatment of **Basal Cell Carcinoma (BCC)**.
- **5-FU (5-Fluorouracil)**: A topical chemotherapeutic agent that interferes with DNA synthesis, specifically used for treating superficial BCC.
- **Imiquimod**: An immune response modifier that stimulates the body's immune system to produce interferon and other cytokines, approved for superficial BCC.
- **Vismodegib**: A **Sonic Hedgehog pathway inhibitor**, used for advanced BCC that is locally advanced or metastatic.
## **Why Each Wrong Option is Incorrect**
- **Option A: Itraconazole** - This is an antifungal medication and not approved for the treatment of BCC.
- **Option B: Azathioprine** - This is an immunosuppressive drug used in organ transplantation and autoimmune diseases, not for BCC.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Basal Cell Carcinoma** is the most common form of skin cancer and is associated with sun exposure. Treatment options vary based on the subtype and extent of the disease, including surgical and non-surgical approaches like topical treatments (5-FU, Imiquimod) and targeted therapy (Vismodegib).
## **Correct Answer:** **B. 1, 2, 5**
Free Medical MCQs Β· NEET PG Β· USMLE Β· AIIMS
Access thousands of free MCQs, ebooks and daily exams.
By signing in you agree to our Privacy Policy.